Widening the Net: The Role of Combination Therapy in Cancer
|
|
- Charles Bryant
- 5 years ago
- Views:
Transcription
1 Widening the Net: The Role of Combination Therapy in Cancer Heather DiBenedetto, MS RAC Global Head of Clinical Operations Translational Clinical Oncology, Novartis July 15, 2015
2 Topics for Discussion Why is cancer different? What is combination therapy? Study Design Regulatory submission Sponsor considerations What is next? 2 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
3 Cancer Why is Cancer Different? It is far from one disease Luminal A Different mutations Breast Lung Melanoma Luminal B TNBC/Basal Her2 Different mutations Different mutations Different mutations 3 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
4 New Therapy A Patient A Patient B Patient C Patient D 20 0 Pretreatment 2 cycles 4 cycles 6 cycles 4 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
5 Tumor Volume New Therapy A After 10 cycles Time of Relapse Patient A Patient B Patient C Patient D 0 5 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
6 Combination Therapy When drugs with different effects are combined, each drug can be used at its optimal dose, without intolerable side effects. For some cancers, the best approach is a combination of surgery, radiation therapy, and chemotherapy.* *Definition of Combination Drug Therapy-The Merck Manuals 6 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
7 Promise of Combination Oncology Trials Cancer trial of drug combination yields 'spectacular' results The Guardian, June Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer NIH, June 2014 Combination Effective in Advanced Melanoma; Cost Questions Raised ASCO Daily News, May Study: Combination Therapy Could Revolutionize Cancer Treatment Voice of America, June 2013 Exploring the Pathway: The RAS/RAF/ME K/ERK Pathway in Cancer: Combination Therapies and Overcoming Feedback ASCO Daily News, May DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
8 Is Cancer smarter than us? No problemeasy escape 8 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
9 Escape Mechanisms 2. Escape mechanism used and function restored ABC pathway 1. Drug blocks downstream effect 9 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
10 Combination Therapy A + B After 12 cycles Patient A Patient B Patient C Patient D 0 10 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
11 Combination Therapy in Melanoma Royal Marsden patient Vicky Brown s CT scan before treatment (left) and 12 weeks after initial treatment. Photograph: Royal Marsden 11 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
12 Study Design in Drug Combination Therapy One size does not fit all-small molecule, biologics, immunotherapy Novel agent + Novel agent Novel agent + Standard of Care Novel agent + approved agent in a new indication 12 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
13 Study Design in Drug Combination Therapy What data already exists for the compounds? Dose escalation Both agents vs. anchor agent Information from single agent Overlapping risks= Low starting dose Dosing Single Agent Signal seeking Combination in same study Multiple arms Crossover Randomization 13 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
14 Sponsor Considerations in Combinations More complexity Clinical documents Consistency across program More frequent updates, amendments Risk document Drug/Drug interactions More conmed exclusions More assessments Increased monitoring Drug Supply and comliance Naming conventions System limitations Protocol ICF Patient Information Drug Diary 14 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
15 Patient Considerations in Combinations Making a complex study work on a patient level Informed consent form Sample collection Safety, PK, biomarker Blood, Skin, Tumor, Hair, Urine Drug administration Dose strength, pill color, patient kits Patient Tools Appointment reminders, drug diary, instructions, calendar Assessment schedule Long days, multiple visits to clinic 15 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
16 Looking to the future Genetic tumor profiling for all patients Combinations earlier in treatment More immunotherapy Understanding resistance mechanisms and adaptive responses Quest to CURE cancer and not just slow it 16 DiBenedetto/ Arena Oncology Conference/Day 2/July 2015
17 Heather DiBenedetto The messages in this presentation represent my own opinion and not necessarily that of Novartis
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationOncolytic Viruses: Reovirus
T S X : O N C N A S D A Q : O N C Y International Society for Biological Therapy of Cancer 2008 Oncology Biologics Development Primer Oncolytic Viruses: Reovirus REOLYSIN - mode of action REOLYSIN contains
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationImmunotherapy. A Cancer Treatment Option
Immunotherapy A Cancer Treatment Option Introduction CureSearch for Children s Cancer has partnered with Dr. Jennifer Dean to share about immunotherapy, a revolutionary treatment that uses a patient s
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationIs there a Cookbook for Oncology Clinical Trials?
Masterclass for Masters See beyond : An Oncology Brainstorm Ghent, 16th of September 2016 Is there a Cookbook for Oncology Clinical Trials? Dimitrios Zardavas MD Associate Scientific Director, Breast International
More informationWhat s the Latest in Prostate Cancer Immunotherapy Options?
What s the Latest in Prostate Cancer Immunotherapy Options? Jeri Kim, MD Associate Professor, Department of Geritourinary Medical Oncology The University of Texas MD Anderson Cancer Center Sumit K. Subudhi,
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationNSGO CLINICAL TRIALS IN OVARIAN CANCER UPDATE
NSGO CLINICAL TRIALS IN OVARIAN CANCER UPATE Niraparib and niraparibbevacizumab combination against bevacizumab alone in Women with Homologous Recombination eficient (HR) platinumsensitive epithelial ovarian,
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationCancer diagnosis and treatments- brief overview of the changing paradigm.
Cancer diagnosis and treatments- brief overview of the changing paradigm. Pranshu Bansal MD New Mexico Cancer Center Identifying cancer in clinic Most common cancers are lung, breast, colon, prostate and
More informationLearning from the Impact of the Drug-Diagnostics Strategy in Oncology
Learning from the Impact of the Drug-Diagnostics Strategy in Oncology Critical Path to TB Drug Regimens 2017 Workshop Washington DC March 22, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationDoctor office visit checklist
Doctor office visit checklist Before the visit Gather your questions Identify symptoms Check your loved one s file Call to confirm appointment Take a list of any medicines the patient is currently taking
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
National Institute for Health and Care Excellence Single Technology Appraisal (STA) Nivolumab for treating advanced (unresectable or metastatic) melanoma At the scoping consultation stage, the scopes for
More information2017 Annual Report CANCER CENTER
2017 Annual Report CANCER CENTER New Lung Cancer Cases-2016 Lung cancer is the leading cause of cancer deaths, among both men and women, in the United States - claiming more lives each year than colon,
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationUnderstanding Tumor Markers for Breast and Colorectal Cancers. A Patient s Guide. Recommendations of the American Society of Clinical Oncology
Cover Layout 1 A Patient s Guide Understanding Tumor Markers for Breast and Colorectal Cancers Recommendations of the American Society of Clinical Oncology ... Cover Layout 2 A Patient s Guide Understanding
More informationimage Empower Yourself With Knowledge for managing advanced prostate cancer
image Empower Yourself With Knowledge 7 Principles for managing advanced prostate cancer Where the mind goes... the body follows. Bill Blair, founder of Mets Mavericks, an Us TOO support group formed to
More informationEvolution of Early Phase Trials: Clinical Trial Design in the Modern Era
Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational
More informationIOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
More informationFrankly Speaking About Cancer Clinical Trials
Frankly Speaking About Cancer Clinical Trials Medical Review The following slides were medically reviewed by Brad Hirsch, MD, in March 2017. Workshop Overview What is a clinical trial? Why clinical trials
More informationInformation Release Form
Information Release Form Name: Date: Contact Preferences By signing below I give permission to Whole Health Chiropractic to leave messages regarding my appointments, nutrition, or other health information
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMY LUNG CANCER CARE PLAN
MY LUNG CANCER CARE PLAN MANAGE DIAGNOSIS TRACK TREATMENTS & APPOINTMENTS MONITOR SYMPTOMS FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers We are Free
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 19: October 13, 2010 Coming soon: RTOG 0929, A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
More informationCHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling
CHK1 Inhibitor Prexasertib, LY2606368 MsOH H 2 O Derived from Garrett MD and Collins I 1 ; Thompson R and Eastman A. 2 Drug Discovery Platform: Cancer Cell Signaling A Phase 2 Study of LY2606368 in Patients
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationWhat is cancer? l Cancer is a group of several diseases caused by the abnormal growth of cells.
Cancer Biology What is cancer? l Cancer is a group of several diseases caused by the abnormal growth of cells. What is cancer? l Cancer is a group of several diseases caused by the abnormal growth of cells.
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationULTIMATE GBG 95 UC-0140/1606 BIG UnLock The IMmune cells ATtraction in ER+ breast cancer
ULTIMATE GBG 95 UC-0140/1606 BIG 16-01 UnLock The IMmune cells ATtraction in ER+ breast cancer A PHASE II TRIAL TESTING DURVALUMAB COMBINED WITH ENDOCRINE THERAPY IN PATIENTS WITH ER+/HER2- BREAST CANCER
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationSCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017
Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationThe Clinical Research E-News
ISSUE 18: September 9, 2009 New Activations: The Clinical Research E-News SWOG0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationOpportunity and Challenge
Opportunity and Challenge Implementation of Comparative Effectiveness Research: The Patient Protection and Affordable Care Act Dr. Ellen V. Sigal, Chair & Founder, Friends of Cancer Research Comparative
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationTIPS FOR GETTING THE MOST OUT OF YOUR TREATMENT.
Keeping it Real. TIPS FOR GETTING THE MOST OUT OF YOUR TREATMENT. Guiding you through your treatment Taking KISQALI (ribociclib) as prescribed is essential to getting the most out of your treatment. That
More informationPassport to Health Preventing and Recognizing Gynecologic Cancers
Passport to Health Preventing and Recognizing Gynecologic Cancers Presented by: Obstetrician/Gynecologist Leigh Bauer, M.D. They can sneak up on you. 2 Gynecologic cancers, that is. Knowing the facts can
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationCenter for Cell Therapy and Regenerative Medicine (CCRG)
Center for Cell Therapy and Regenerative Medicine (CCRG) What is CCRG? CCRG is a multidisciplinary platform for new types of cellular therapy and tissue therapy. It is located on the campus of the Antwerp
More informationHighlights of these abstracts are presented below:
PharmaMar announces the presentation of 15 abstracts on Yondelis and Aplidin at the 46 th annual meeting of the American Society of Clinical Oncology (ASCO) Madrid, 9 June 2010: PharmaMar SA (Grupo Zeltia,
More informationOral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center
Oral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center Learning Objectives Review strategies, tools, and resources to facilitate adherence among patients
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationSNMMI House of Delegates Bi-Annual Report Computer and Instrumentation Council Goals 2017 Mid-Winter Meeting
SNMMI House of Delegates Bi-Annual Report Computer and Instrumentation Council Goals 2017 Mid-Winter Meeting Overview: SNMMI Councils and Centers provide professional networking and educational programs
More informationLurie Cancer Center (LCC) OncoSET: Bringing Real-Time Precision Medicine to Patients
Lurie Cancer Center (LCC) OncoSET: Bringing Real-Time Precision Medicine to Patients Massimo Cristofanilli, MD Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationTITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention
AD (Leave blank) Award Number: W81XWH-10-1-0175 TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention PRINCIPAL INVESTIGATOR: Eleanor G. Rogan, Ph.D. CONTRACTING
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More informationSNMMI House of Delegates Bi-Annual Report Computer and Instrumentation Council Goals 2017 Annual Meeting
SNMMI House of Delegates Bi-Annual Report Computer and Instrumentation Council Goals 2017 Annual Meeting Overview: SNMMI Councils and Centers provide professional networking and educational programs for
More informationASCO 2016: Ask the Lung Cancer Experts
Live @ ASCO 2016: Ask the Lung Cancer Experts Charu Aggarwal, MD, MPH Assistant Professor of Medicine University of Pennsylvania Health System Liza Villaruz, MD Hematology/Oncology Specialist University
More informationOncology member story: Barbara
Oncology member story: Barbara The results from an initial mammogram concerned doctors enough that Barbara* was scheduled for a follow-up appointment for further investigation. A few months later, a sonogram
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationFuture Therapeutic Developments in Head and Neck Cancer
Future Therapeutic Developments in Head and Neck Cancer Professor Kevin Harrington Joint Head of Division of Radiotherapy and Imaging The Institute of Cancer Research/The Royal Marsden NIHR Biomedical
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationAnd so, why should we hear about triple negative breast cancer, what is special about it, aside from the fact that it does not have these receptors?
1 Support for Yale Cancer Answers is provided by AstraZeneca, working to pioneer targeted lung cancer treatments and advanced knowledge of diagnostic testing. More information at astrazeneca-us.com Welcome
More informationTargeted Therapies For Renal Cell Carcinoma
Targeted Therapies For Renal Cell Carcinoma If searched for the ebook Targeted Therapies for Renal Cell Carcinoma in pdf form, in that case you come on to the correct site. We presented utter option of
More informationSpontaneous canine malignancies: Models for precision cancer medicine
National Cancer Institute Spontaneous canine malignancies: Models for precision cancer medicine Amy K. LeBlanc, DVM DACVIM (Oncology) Director, NCI Comparative Oncology Program NIH/NCI Center for Cancer
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within
More informationRecommendations. for Care of Adults with Epilepsy. Seeking the best treatment from the right doctor at the right time!
Recommendations for Care of Adults with Epilepsy Seeking the best treatment from the right doctor at the right time! Contents This booklet is to help adults and their caregivers know when it is appropriate
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationNSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania
NSABP B-55/BIG 6-13 Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department NRG Oncology - Pittsburgh, Pennsylvania NRG Oncology Meeting July 15, 2016 Lynne Suhayda, RN, MSEd. No Financial
More informationHow is Merck supporting innovation in oncology?
How is Merck supporting innovation in oncology? We sponsor research and advanced medical education globally, reflecting our commitment to science, education and patient care We support the development
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationEstablishing survivorship care in a community-based center
Establishing survivorship care in a community-based center When should survivorship care begin? The definition of a cancer survivor and strategies for educating and engaging survivors in their care are
More informationCTA Strengths. Organisational Structure Board. CTA Board CEO. Background to Cancer Trials Australia What we do well An increasing struggle Conclusions
Models for Clinical Research: Cancer Trials Australia Professor Mark Rosenthal Chairman; Cancer Trials Australia and Director of Medical Oncology, Royal Melbourne Hospital For discussion: Background to
More informationChallenges In The Development Of Novel Therapeutics In Ovarian Cancer Tony Ho, MD Global Medicine Leader Medi4736, Vice President, AstraZeneca
Challenges In The Development Of Novel Therapeutics In Ovarian Cancer Tony Ho, MD Global Medicine Leader Medi4736, Vice President, AstraZeneca The views and opinions expressed herein are my own and do
More informationFine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013
Fine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013 John Corman, M.D. Medical Director, Floyd & Delores Jones Cancer Institute at Virginia Mason Virginia Mason Medical Center
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationBreast and Ovarian Cancer
Patient Education Breast and Ovarian Cancer Screening and detection The goal of screening for cancer is to find it as early as possible, when it is easiest to cure. This handout describes the symptoms
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationLung Cancer: Current And Emerging Trends In Detection And Treatment (Cancer And Modern Science) By Julie Walker READ ONLINE
Lung Cancer: Current And Emerging Trends In Detection And Treatment (Cancer And Modern Science) By Julie Walker READ ONLINE If searching for a book by Julie Walker Lung Cancer: Current and Emerging Trends
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationAddressing Breast Cancer's High Recurrence Rates: The Breast Cancer Translational Center of Excellence (TCE)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/addressing-breast-cancershigh-recurrence-rates-breast-cancer-translational-center-excellence-tce/7981/
More informationRole of Patient Navigation and A Team Approach to Coordinated Care June 13, 2016
Role of Patient Navigation and A Team Approach to Coordinated Care June 13, 2016 Mohamed Salem, MD Lana De Leon, BSN, RN Lombardi Comprehensive Cancer Center Georgetown University Washington DC Disclosures
More informationBackgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?
Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 23: December 16, 2010 Coming soon: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More information